uniQure Faces Investor Lawsuit Over Misleading Statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Approaching Lawsuit Deadline: Hagens Berman reminds investors that the Lead Plaintiff Deadline for litigation against uniQure N.V. is April 13, 2026, alleging that the company and its executives made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130.
- FDA Regulatory Issues: The lawsuit claims that uniQure failed to fully disclose that the design of its pivotal study was not fully approved by the FDA, and that the company may face delays in its Biologics License Application (BLA) timeline, impacting future drug launch plans.
- Significant Stock Drop: Following the disclosure on November 3, 2025, that the FDA no longer agrees that AMT-130's data is adequate for BLA submission, uniQure's stock price plummeted over 49%, reflecting strong market concerns about the company's future prospects.
- Investor Rights Protection: Hagens Berman is investigating whether uniQure violated federal securities laws and encourages investors who purchased QURE securities during the Class Period and suffered significant losses to contact the firm for legal support to protect their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 14.270
Low
33.00
Averages
49.88
High
70.00
Current: 14.270
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Stock Surges 36% Despite FDA Criticism
- FDA Criticism Impact: Despite a US FDA official criticizing uniQure on March 5 for a “distorted or manipulated comparison” in its Huntington's disease asset AMT-130 study, the stock surged approximately 36% in premarket trading, indicating market confidence in its future prospects.
- Stock Price Recovery: Following the FDA official's comments, uniQure's share price closed up about 18% on March 5 and added another approximately 34% on March 6, reflecting investor optimism regarding the company's outlook.
- Clinical Trial Requirement: The FDA has requested uniQure to conduct a phase 3 trial, which may increase R&D costs in the short term but also provides an opportunity for the company to further validate its product's efficacy, potentially enhancing market acceptance in the long run.
- Leadership Change Impact: The stock price increase is partly attributed to the upcoming departure of Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, in April, with the market generally viewing this change as potentially improving the company's relationship with the FDA, thereby benefiting the approval process for AMT-130.
See More
uniQure Faces Investor Lawsuit Over Misleading Statements
- Approaching Lawsuit Deadline: Hagens Berman reminds investors that the Lead Plaintiff Deadline for litigation against uniQure N.V. is April 13, 2026, alleging that the company and its executives made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130.
- FDA Regulatory Issues: The lawsuit claims that uniQure failed to fully disclose that the design of its pivotal study was not fully approved by the FDA, and that the company may face delays in its Biologics License Application (BLA) timeline, impacting future drug launch plans.
- Significant Stock Drop: Following the disclosure on November 3, 2025, that the FDA no longer agrees that AMT-130's data is adequate for BLA submission, uniQure's stock price plummeted over 49%, reflecting strong market concerns about the company's future prospects.
- Investor Rights Protection: Hagens Berman is investigating whether uniQure violated federal securities laws and encourages investors who purchased QURE securities during the Class Period and suffered significant losses to contact the firm for legal support to protect their rights.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
Class Action Notice for uniQure N.V. Investors
- Class Action Notice: The Portnoy Law Firm advises investors of uniQure N.V. about a class action for those who purchased securities between September 24 and October 31, 2025, with a deadline of April 13, 2026, for filing a lead plaintiff motion to protect their legal rights.
- FDA Feedback Impact: On November 3, 2025, uniQure disclosed that the FDA indicated during a recent BLA meeting that data from AMT-130's clinical trials may not be sufficient for BLA submission, marking a significant shift in the company's regulatory outlook and creating uncertainty around the submission timeline.
- Stock Price Plunge: Following the FDA's negative feedback, uniQure's stock price fell by $33.40, or 49.34%, closing at $34.29 per share on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Legal Support Services: The Portnoy Law Firm offers complimentary case evaluations to assist investors in pursuing claims for losses due to corporate wrongdoing, demonstrating the firm's commitment to protecting investor rights and interests.
See More
uniQure's AMT-130 Faces New FDA Challenges Amid Upgrades
- FDA New Requirements: The FDA recently indicated that data from uniQure's Phase I/II trials were insufficient, recommending a new randomized Phase III study, which could delay AMT-130's market entry and impact future revenue expectations.
- Significant Stock Surge: Shares of uniQure surged over 20% on Monday due to optimistic regulatory outlooks from Wall Street analysts, with Wells Fargo upgrading its rating from 'Equal Weight' to 'Overweight' and raising its price target from $15 to $60, implying a potential 243% upside.
- Key Personnel Change: FDA Chief Medical and Scientific Officer Vinay Prasad is expected to leave next month, and Wells Fargo believes this could reopen a more balanced discussion regarding the risk-benefit profile of AMT-130, enhancing its chances of approval.
- Positive Early Data: Despite regulatory challenges, AMT-130 has shown promising early results, with patients receiving high doses experiencing about a 75% slower rate of disease progression over three years, laying a solid foundation for future market commercialization.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
uniQure Stock Surges 36% Despite FDA Criticism
- FDA Criticism Impact: Despite a US FDA official criticizing uniQure on March 5 for a “distorted or manipulated comparison” in its Huntington's disease asset AMT-130 study, the stock surged approximately 36% in premarket trading, indicating market confidence in its future prospects.
- Stock Price Recovery: Following the FDA official's comments, uniQure's share price closed up about 18% on March 5 and added another approximately 34% on March 6, reflecting investor optimism regarding the company's outlook.
- Clinical Trial Requirement: The FDA has requested uniQure to conduct a phase 3 trial, which may increase R&D costs in the short term but also provides an opportunity for the company to further validate its product's efficacy, potentially enhancing market acceptance in the long run.
- Leadership Change Impact: The stock price increase is partly attributed to the upcoming departure of Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, in April, with the market generally viewing this change as potentially improving the company's relationship with the FDA, thereby benefiting the approval process for AMT-130.
See More
uniQure Faces Investor Lawsuit Over Misleading Statements
- Approaching Lawsuit Deadline: Hagens Berman reminds investors that the Lead Plaintiff Deadline for litigation against uniQure N.V. is April 13, 2026, alleging that the company and its executives made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130.
- FDA Regulatory Issues: The lawsuit claims that uniQure failed to fully disclose that the design of its pivotal study was not fully approved by the FDA, and that the company may face delays in its Biologics License Application (BLA) timeline, impacting future drug launch plans.
- Significant Stock Drop: Following the disclosure on November 3, 2025, that the FDA no longer agrees that AMT-130's data is adequate for BLA submission, uniQure's stock price plummeted over 49%, reflecting strong market concerns about the company's future prospects.
- Investor Rights Protection: Hagens Berman is investigating whether uniQure violated federal securities laws and encourages investors who purchased QURE securities during the Class Period and suffered significant losses to contact the firm for legal support to protect their rights.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
Class Action Notice for uniQure N.V. Investors
- Class Action Notice: The Portnoy Law Firm advises investors of uniQure N.V. about a class action for those who purchased securities between September 24 and October 31, 2025, with a deadline of April 13, 2026, for filing a lead plaintiff motion to protect their legal rights.
- FDA Feedback Impact: On November 3, 2025, uniQure disclosed that the FDA indicated during a recent BLA meeting that data from AMT-130's clinical trials may not be sufficient for BLA submission, marking a significant shift in the company's regulatory outlook and creating uncertainty around the submission timeline.
- Stock Price Plunge: Following the FDA's negative feedback, uniQure's stock price fell by $33.40, or 49.34%, closing at $34.29 per share on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Legal Support Services: The Portnoy Law Firm offers complimentary case evaluations to assist investors in pursuing claims for losses due to corporate wrongdoing, demonstrating the firm's commitment to protecting investor rights and interests.
See More
uniQure's AMT-130 Faces New FDA Challenges Amid Upgrades
- FDA New Requirements: The FDA recently indicated that data from uniQure's Phase I/II trials were insufficient, recommending a new randomized Phase III study, which could delay AMT-130's market entry and impact future revenue expectations.
- Significant Stock Surge: Shares of uniQure surged over 20% on Monday due to optimistic regulatory outlooks from Wall Street analysts, with Wells Fargo upgrading its rating from 'Equal Weight' to 'Overweight' and raising its price target from $15 to $60, implying a potential 243% upside.
- Key Personnel Change: FDA Chief Medical and Scientific Officer Vinay Prasad is expected to leave next month, and Wells Fargo believes this could reopen a more balanced discussion regarding the risk-benefit profile of AMT-130, enhancing its chances of approval.
- Positive Early Data: Despite regulatory challenges, AMT-130 has shown promising early results, with patients receiving high doses experiencing about a 75% slower rate of disease progression over three years, laying a solid foundation for future market commercialization.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
